NVSNovartis AG
$151.11+19% 1Y
$151.11
$118.2052 weeks$163.64
Is the price fair?
What NVS's price assumes
Novartis AG has no trailing P/E on file, so the price is measured against sales instead: 3.17× revenue.
3.17
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 5.53
Price / book · as of 2025-H2
- EV / sales
- 3.39
EV / sales
Details›
- Price / bookas of 2025-H2
- 5.53
- EV / EBITas of 2025-H2
- 11.0
- EV / salesas of 2025-H2
- 3.39
- Market capitalisation1.91 billion shares, counted Dec 31, 2025
- $288.3B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, General
Ranks #2 of 7 by RyuScore